360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Bristol-Myers Squibb Company

Type: Company

Name: Bristol-Myers Squibb Company (Bristol Myers Squibb Co)

Nationality: United States

Web Address: http://www.bms.se

Fact Sheet: Fact Sheet for Bristol Myers Squibb Co

First reported 13 hours ago - Updated 5 hours ago - 3 reports

Roche Holding AG

Cancer cocktail shows promise

Two drugs from Bristol-Myers Squibb (BMY), taken together, shrank tumors in melanoma patients. Tumors shrank in 53% of patients who got the most effective dose of a combination of the company's melanoma drug Yervoy and nivolumab, its experimental treatment ... [Published Yahoo! Finance - 5 hours ago]

Entities: Bristol-Myers Squibb Company, Cancer, Roche Holding AG, Skin Cancer

First reported 11 hours ago - Updated 11 hours ago - 1 reports

New Findings in Hepatitis C Virus Described from Bristol-Myers Squibb

(NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Investigators publish new report on Liver Diseases and Conditions. According to news originating from Wallingford, Connecticut, by NewsRx correspondents, research stated, "Hepatitis ... [Published NewsRX - 11 hours ago]

Entities: Hepatitis C Virus, Bristol-Myers Squibb Company, Genotype, Antiviral, RNA

First reported 17 hours ago - Updated 12 hours ago - 2 reports

New York Stock Exchange

Bristol-Myers Squibb Company Announces Intention to Voluntarily Delist Preferred Stock

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has notified the New York Stock Exchange (âNYSEâ) of its intention to voluntarily delist its $2 Convertible Preferred Stock (the âPreferred Stockâ) from the NYSE. ... [Published BioSpace - 12 hours ago]

Entities: Bristol-Myers Squibb Company, Preferred Shares, New York Stock Exchange

First reported 14 hours ago - Updated 14 hours ago - 1 reports

BristolMyers Merck And Roche R&D Finds Golden Pill So Buy

Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So BuyHome » Blogs » Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So BuyWe had great news today (Thursday), but the response was tepid. Rather than being disappointed or dismissing the news, ... [Published BioPortfolio - 14 hours ago]

Entities: Research & Development, Bristol-Myers Squibb Company, Cancer, Biotechnology, Drugs

First reported May 16 2013 - Updated 17 hours ago - 11 reports

My “truly remarkable” cancer breakthrough

I?ve spent my whole career trying to make some kind of a name for myself. But it turns out that if I am remembered for anything, it will likely be as a number. My patient number is how I?m identified in the . It protects my privacy as doctors and researchers ... [Published Salon - 17 hours ago]

Entities: Cancer, Tumor, Patient

First reported 20 hours ago - Updated 20 hours ago - 1 reports

Bristol-Myers Squibb Company

Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA (Efavirenz) in HIV-1 Infected Pediatric Patients

Bristol-Myers Squibb Press Release (05/03/13)body: The FDA has approved a supplemental new drug application (sNDA) for Bristol-Myers Squibb's HIV-1 treatment efavirenz (Sustiva). The sNDA calls for efarivenz to be given once a day to children with HIV-1 ... [Published AAPS Pharmceutica - 20 hours ago]

Entities: Sustiva, Efavirenz, Bristol-Myers Squibb Company

First reported 21 hours ago - Updated 21 hours ago - 1 reports

"Bristol-Myers Squibb de Mexico SA de CV in Hot Drinks (Mexico)" is now available at Fast

(live-PR.com) - US-based Bristol-Myers Squibb is one of the largest pharmaceutical companies in the world and is a major player in pharmaceuticals (OTC and prescription medicines) and consumer healthcare in Mexico. However, the company is not involved ... [Published Live-PR.com - 21 hours ago]

Entities: Bristol-Myers Squibb Company, Mexico, Stocks, Competitive Intelligence, Vilnius

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Bristol-Myers Squibb Targets Heart-Failure Drugs in R&D Effort

Bristol-Myers Squibb is planning on starting new initiatives to study drugs aimed at treating fibrosis and congestive heart failure. The company is also refusing to give up on Alzheimer?s disease treatment after a failed trial. Bloomberg Full Issue ... [Published FDA News - May 17 2013]

Entities: Bristol-Myers Squibb Company, Research & Development, Drugs

First reported May 16 2013 - Updated May 16 2013 - 1 reports

UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform

1:55 PM EDT)Leerink Swann upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Market Perform to Outperform. The upgrade follows an evaluation of information in the ASCO news release published yesterday."Specifically, 5 additional deep responses (80% tumor ... [Published Street Insider - May 16 2013]

Entities: Bristol-Myers Squibb Company, Leerink Swann & Co Inc, Seamus Fernandez, evaluable patients

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology

Development program for nivolumab now includes seven potentially registrational trials in non-small-cell lung cancer, advanced melanoma and renal cell carcinoma. 05/16/2013 ... [Published News from Kidney Cancer Association - May 16 2013]

Entities: Bristol-Myers Squibb Company, Leadership, renal cell carcinoma

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Bristol Myers (BMY) Showing Bullish Technicals With Support At $40.60

Bristol-Myers Squibb Co (NYSE: BMY) closed Wednesday's trading session at $44.34. In the past year, the stock has hit a 52-week low of $30.64 and 52-week high of $45.59. Bristol Myers (BMY) stock has been showing support around $40.60 and resistance in ... [Published MarketIntelligenceCenter.com - May 16 2013]

Entities: Bristol-Myers Squibb Company, New York Stock Exchange

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Bristol-Myers Squibb (BMY) Rose Past Resistance At The Highs

Bristol-Myers Squibb (BMY: Quote) climbed throughout the first half of Wednesday's session, before settling into a range. The stock closed up by 2.13 at $44.34 on strong volume.Bristol-Myers Squibb rose past the upper end of a month and a half long range ... [Published RTTNews.com - May 16 2013]

Entities: Bristol-Myers Squibb Company

Quotes

Midwest Fertilizer released a statement saying it's, "optimistic, working together with the Posey County Economic Development Partnership and the Economic Development Coalition of Southwest Indiana, that a joint effort will be successful."

Posey County Official Optimistic About Proposed Fertilizer Plant [Published WTVW FOX 7 - 1 hour ago]

Included in the recent update on L-BLP25 was this information on PX-866 as shown by Yahoo here. "Co also announced data from two single-arm Phase II trials of PX-866 in patients with glioblastoma (GBM) and castration resistant prostate cancer (CRPC), respectively. In the GBM trial 33 patients with a first recurrence after chemoradiation and adjuvant temozolomide were given PX-866 8 mg daily. MRI and clinical exam were done every cycle (8 weeks). All patients were evaluable for response - 25 had a best response of progression, 1 had a partial response (overall response rate 3%) and seven (21%) had stable disease (median 7.3 months; range 3.1-13.6). Six month progression free survival was 17%. PX-866 was relatively well tolerated. Adverse effects included liver function test abnormalities, fatigue, diarrhea, nausea, vomiting and lymphopenia. In the CRPC trial 43 patients not previously treated with docetaxel received PX-866, 8mg daily on a 6-week cycle. The primary endpoint was lack of progression at 12 weeks (PCWG2 criteria). Secondary endpoints included PSA and objective response rates and change in circulating tumor cells (CTC) during treatment. Eleven patients were progression free at 12 weeks. Sixteen of the 24 patients with measurable disease were evaluable for response; there were no objective responses but 10 patients had stable disease (2.6-13.9 months). One patient had a confirmed PSA response. CTC favorable conversion (from 5 at baseline to 5) was observed in 6 of 24 evaluable patients (25%). PX-866 was well-tolerated. Adverse events included diarrhea, nausea, fatigue, vomiting, anorexia, hypomagnesemia and liver function test abnormalities." With preliminary performance such as this, the increased interest and success in the immunotherapy space, and the pipeline, I would put weight to the...

Oncothyreon A Speculative Buy [Published Seeking Alpha - 4 hours ago]

"Lots of outsiders think Connecticut is all yachts and I-bankers on the eastern side, and here in central CT you have crime" Koch says. "That impression is just wrong." Well, not entirely: Last year, New Haven was ranked the fourth most dangerous city in the United States...

How LinkedIn's Reid Hoffman Jumped Off A Cliff And Built An Airplane [Published Fast Company - 8 hours ago]

"The complete and near-complete response rates we're seeing are unprecedented for an immunotherapy in melanoma" Wolchok said in a statement

ASCO: combo antibody therapy effective for melanoma [Published Medical Xpress - 9 hours ago]

More Content

sort by: Date \| Relevance
Posey County Official Optimistic About Proposed... [Published WTVW FOX 7 - 1 hour ago]
Oncothyreon A Speculative Buy [Published Seeking Alpha - 4 hours ago]
Cancer cocktail shows promise [Published Yahoo! Finance - 5 hours ago]
Pharmaceutical company fined in deaths of 2 mon... [Published New Jersey Online - 5 hours ago]
How LinkedIn's Reid Hoffman Jumped Off A Cliff ... [Published Fast Company - 8 hours ago]
Stocks End Near Session Highs; Post Gains for t... [Published futuresource.com - 8 hours ago]
Bristol Myers: New Drugs Show Promise, Plavix P... [Published Trefis - 9 hours ago]
ASCO: combo antibody therapy effective for mela... [Published Medical Xpress - 9 hours ago]
Techquity: Yahoo could tumble with Tumblr, Tim ... [Published Reuters India - 10 hours ago]
New Findings in Hepatitis C Virus Described fro... [Published NewsRX - 11 hours ago]
Bristol-Myers Squibb Company Announces Intentio... [Published BioSpace - 12 hours ago]
Bristol-Myers Squibb drug study showed effectiv... [Published New Jersey Online - 13 hours ago]
Drug manufacturing problems and malfeasance spa... [Published Philly.com - 13 hours ago]
Quick Take: The Next Big Thing in Biotech [Published TheStreet.com - 14 hours ago]
BristolMyers Merck And Roche R&D Finds Golden P... [Published BioPortfolio - 14 hours ago]
Stock Upgrades And Downgrades: AMAT, ARUN, BMY,... [Published I Stock Analyst - 15 hours ago]
US EQUITIES OPENING HEADLINES INCLUDING: Wall S... [Published Proactiveinvestors United Kingdom RSS feed - 15 hours ago]
AbbVie (ABBV) Has Plenty More Tricks Up Its Sle... [Published Street Insider - 16 hours ago]
US Embassy, USAID Will Attend 14th Conference o... [Published Hondurasweekly - 17 hours ago]
My “truly remarkable” cancer breakthrough [Published Salon - 17 hours ago]
Bristol-Myers Squibb to voluntarily delist Pref... [Published Zecco - 17 hours ago]
Indian essential drug prices to fall "up to 80%" [Published Pharma Times - 17 hours ago]
Bristol-Myers, Merck And Roche: R&D Finds Golde... [Published Seeking Alpha - 17 hours ago]
Biotech Stock Mailbag: Vical, Sangamo, Spectrum... [Published TheStreet.com - 18 hours ago]
OPTIMIZERX CORPORATION(NDA): SampleMD Connectin... [Published 4 Traders - 20 hours ago]
Bristol-Myers Squibb Receives US FDA sNDA Appro... [Published AAPS Pharmceutica - 20 hours ago]
Edward J. Meyer, longtime executive [Published Individual.com - 21 hours ago]
"Bristol-Myers Squibb de Mexico SA de CV in Hot... [Published Live-PR.com - 21 hours ago]
2 melanoma drugs show promise in clinical study [Published Journal-Gazette - 22 hours ago]
Edward J. Meyer, longtime executive [Published Philadelphia Daily News - 22 hours ago]

Blogs

sort by: Date \| Relevance
Analysts: Bristol-Myers Shares Will Give Back G... [Published Wall St. Cheat Sheet - May 16 2013] Bristol-Myers ( NYSE:BMY ): Leerink believes that shares will give back recent gains after ASCO published abstracts last night. Leerink saw the abstracts as being in line, but not above its expectations for nivolumab alone or immuno-oncology combination ...
Analysts: Bristol-Myers Shares Will Give Back G... [Published Wall St. Cheat Sheet - May 16 2013] Bristol-Myers ( NYSE:BMY ): Leerink believes that shares will give back recent gains after ASCO published abstracts last night. Leerink saw the abstracts as being in line, but not above its expectations for nivolumab alone or immuno-oncology combination ...
Bristol-Myers Squibb Advances Leadership Positi... [Published News from Kidney Cancer Association - May 16 2013] Development program for nivolumab now includes seven potentially registrational trials in non-small-cell lung cancer, advanced melanoma and renal cell carcinoma. 05/16/2013 ...
Bristol Myers (BMY) Showing Bullish Technicals ... [Published MarketIntelligenceCenter.com - May 16 2013] Bristol-Myers Squibb Co (NYSE: BMY) closed Wednesday's trading session at $44.34. In the past year, the stock has hit a 52-week low of $30.64 and 52-week high of $45.59. Bristol Myers (BMY) stock has been showing support around $40.60 and resistance in ...
4 Healthcare Stock Stories Prescribed for Inves... [Published Wall St. Cheat Sheet - May 15 2013] Boston Scientific Corporation ( NYSE:BSX ): Closing price $9.12 The initial patient has been enrolled in a clinical investigation studying the use of the company’s WallFlex Biliary RX Stent, which is a self-expanding metal stent, as a bridge to surgery ...

Audio/Video

sort by: Date \| Relevance
Bristol-Myers Squibb Matches EPS Estimates [Published FOX Business - Video - Apr 25 2013]
Fireside Chat with N. Anthony Coles, MD, Chairm... [Published BIO Channel - YouTube - Feb 27 2013]
N. Anthony Coles, MD, Chairman & CEO, Onyx Phar... [Published BIO Channel - YouTube - Feb 26 2013]
Fireside Chat with N. Anthony Coles, MD, Chairm... [Published BIO Channel - YouTube - Feb 20 2013]
Abby Joseph Cohen's Contrarian View on Deficits [Published WSJ.com Video - News - Jan 26 2013]

Press Releases

sort by: Date \| Relevance
Bristol-Myers Squibb Announces Intention to Vol... [Published Business Wire - May 16 2013]
Bristol-Myers Squibb Announces Intention to Vol... [Published Business Wire Professional Services News - May 16 2013]
Bristol-Myers Squibb Announces Intention to Vol... [Published Business Wire Health News - May 16 2013]
Insider Trading Recap for Bristol Myers Squibb,... [Published Financial Services - May 16 2013]
Bristol-Myers Squibb to Hold Investor Teleconfe... [Published Business Wire Science: Science News - May 15 2013]